The time is now: Achieving FH paediatric screening across Europe – The Prague Declaration

Logo poskytovatele

Varování

Publikace nespadá pod Filozofickou fakultu, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

BEDLINGTON Nicole ABIFADEL Marianne BEGER Birgit BOURBON Mafalda BUENO Héctor CESKA Richard CILLÍKOVÁ Kristýna CIMICKÁ Zdenka DACCORD Magdalena BEAUFORT Carine de DHARMAYAT Kanika I FERENCE Brian A FREIBERGER Tomáš GEANTA Marius GIDDING Samuel S GROŠELJ Urh HALLE Martin JOHNSON Neil NOVAKOVIC Tanja MÁJEK Ondřej PALLIDIS Athanasios PERETTI Noel PINTO Fausto J RAY Kausik Kosh REES Bleddyn REEVE John REINER Željko SANTOS Raul D SCHUNKERT Heribert ŠIKONJA Jaka SOKOLOVIC Milka TOKGÖZOGLU Lale VRABLÍK Michal WIEGMAN Albert GUTIÉRREZ-IBARLUZEA Inaki

Rok publikování 2022
Druh Článek v odborném periodiku
Časopis / Zdroj GMS health innovation and technologies
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://www.egms.de/static/en/journals/hta/2022-16/hta000136.shtml
Doi http://dx.doi.org/10.3205/hta000136
Klíčová slova CVD; CVH; EU; EU best practice; Europe; FH; cardiovascular disease; cardiovascular health; children; declaration; familial hypercholesterolaemia; health systems; implementation; prevention; public health; screening
Přiložené soubory
Popis Familial hypercholesterolaemia (FH) is the most common inherited metabolic disorder characterized by high cholesterol and if left untreated leads to premature cardiovascular disease, such as heart attacks. Treatment that begins early in life, particularly in childhood, is highly efficacious in preventing cardiovascular disease and cost-effective, thus early detection of FH is crucial. However, in Europe, less than 10% of people living with FH are diagnosed and even less receive life-saving treatment. The Prague Declaration is a call to action for national and European Union policymakers and decision-makers and a result of the Czech EU Presidency meeting on FH Paediatric Screening (early detection of inherited high cholesterol) at the Czech Senate in Prague on 6th September 2022. It builds on a considerable body of evidence which was discussed at the Technical Meeting under the auspices of the Slovenian EU Presidency in October 2021. The Prague meeting addressed the outstanding barriers to the systematic implementation of FH paediatric screening across Europe. In this article, we present the key points from the Prague meeting and concrete actions needed to move forward.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.